OMV-SIRPα@CaP/GM-CSF also illustrated efficient tumor regression by trained immunity in both MC38 tumor and B16-F10 tumor models with distinct T-cell-mediated immune responses, suggesting the different therapeutic mechanisms for vaccination formulation. The gene discussed is CSF2; the disease is neoplasm.